Reclassification of pathologically upstaged T3a Renal Cell Carcinoma is associated with enhanced alignment of outcomes: Analysis of the National Cancer Database.

IF 2.4 3区 医学 Q3 ONCOLOGY
Dhruv Puri, Brian R Lane, Natalie Birouty, Luke Wang, Margaret F Meagher, Julian Cortes, Melis Guer, Mimi Nguyen, Aaron Ahdoot, Mai Dabbas, Jonathan Afari, Kit Yuen, Cesare Saitta, Simon Kim, Ithaar H Derweesh
{"title":"Reclassification of pathologically upstaged T3a Renal Cell Carcinoma is associated with enhanced alignment of outcomes: Analysis of the National Cancer Database.","authors":"Dhruv Puri, Brian R Lane, Natalie Birouty, Luke Wang, Margaret F Meagher, Julian Cortes, Melis Guer, Mimi Nguyen, Aaron Ahdoot, Mai Dabbas, Jonathan Afari, Kit Yuen, Cesare Saitta, Simon Kim, Ithaar H Derweesh","doi":"10.1016/j.urolonc.2024.09.010","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To compare outcomes of pathological T3a renal cell carcinoma (RCC) based on clinical stage at presentation, and to propose reclassification of T3a RCC based on survival outcomes, as outcomes of current T3a RCC may vary based on initial clinical presentation.</p><p><strong>Methods: </strong>Using the National Cancer Database, patients with pT2 and pT3aN0M0 RCC were categorized by AJCC clinical T stage. Primary outcome was overall survival (OS). Multivariable analysis (MVA) assessed predictors for all-cause mortality (ACM), controlling for presenting clinical T stage. Kaplan-Meier Analysis (KMA) assessed differences between cT1-upstaged pT3a (cT1→pT3a), cT2-upstaged pT3a (cT2→pT3a), clinical/pathological T2 (cT2→pT2), and clinical/pathological T3a (cT3a→pT3a) RCC, and a modified T3a RCC was created based on clustering of survival outcomes between clinical staging groups. ROC/AUC analysis was utilized to compare predictive value of AJCC 8<sup>th</sup> edition staging vs. proposed staging.</p><p><strong>Results: </strong>45,097 patients with pT3a disease were analyzed (9,730 cT1→pT3a; 7,209 cT2→pT3a, 19,857 cT2→pT2; and 8,301 cT3a→pT3a). MVA for OS [cT1→pT3a (referent)] demonstrated cT2→pT3a (HR=1.27, p<0.001) and cT3a→pT3a (HR=1.20, p<0.001) were associated with worsened ACM, while cT2→pT2 (HR=0.95, p=0.052) was not significantly different. KMA for 5-year OS using current AJCC demonstrated: cT1→pT3a 73.1%, cT2→pT2 78.0%, cT2→pT3a 60.8%, cT3a→pT3a 59.9% (p<0.001). KMA for 5-year OS of a new pT2 group, comprised of cT1→pT3a and cT2→pT2, while maintaining cT2→pT3a and cT3a→pT3a as T3a was 78.0% vs. 60.3% (p=0.003). ROC analysis for OS revealed AUC of 0.532 (95% CI: 0.530-0.535) for T3 using current AJCC 8<sup>th</sup> edition TNM staging and AUC of 0.573 (95% CI: 0.569-0.577) for proposed T3a reclassification (p<0.001).</p><p><strong>Conclusion: </strong>Reclassification of cT1→pT3a and cT2→ pT2 into a new T2 RCC while maintaining cT2→pT3a and cT3a→pT3a RCC in T3a RCC resulted in improved performance of the realigned model for OS. Revised TNM criteria for pT2 and T3a RCC should be considered.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologic Oncology-seminars and Original Investigations","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.urolonc.2024.09.010","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To compare outcomes of pathological T3a renal cell carcinoma (RCC) based on clinical stage at presentation, and to propose reclassification of T3a RCC based on survival outcomes, as outcomes of current T3a RCC may vary based on initial clinical presentation.

Methods: Using the National Cancer Database, patients with pT2 and pT3aN0M0 RCC were categorized by AJCC clinical T stage. Primary outcome was overall survival (OS). Multivariable analysis (MVA) assessed predictors for all-cause mortality (ACM), controlling for presenting clinical T stage. Kaplan-Meier Analysis (KMA) assessed differences between cT1-upstaged pT3a (cT1→pT3a), cT2-upstaged pT3a (cT2→pT3a), clinical/pathological T2 (cT2→pT2), and clinical/pathological T3a (cT3a→pT3a) RCC, and a modified T3a RCC was created based on clustering of survival outcomes between clinical staging groups. ROC/AUC analysis was utilized to compare predictive value of AJCC 8th edition staging vs. proposed staging.

Results: 45,097 patients with pT3a disease were analyzed (9,730 cT1→pT3a; 7,209 cT2→pT3a, 19,857 cT2→pT2; and 8,301 cT3a→pT3a). MVA for OS [cT1→pT3a (referent)] demonstrated cT2→pT3a (HR=1.27, p<0.001) and cT3a→pT3a (HR=1.20, p<0.001) were associated with worsened ACM, while cT2→pT2 (HR=0.95, p=0.052) was not significantly different. KMA for 5-year OS using current AJCC demonstrated: cT1→pT3a 73.1%, cT2→pT2 78.0%, cT2→pT3a 60.8%, cT3a→pT3a 59.9% (p<0.001). KMA for 5-year OS of a new pT2 group, comprised of cT1→pT3a and cT2→pT2, while maintaining cT2→pT3a and cT3a→pT3a as T3a was 78.0% vs. 60.3% (p=0.003). ROC analysis for OS revealed AUC of 0.532 (95% CI: 0.530-0.535) for T3 using current AJCC 8th edition TNM staging and AUC of 0.573 (95% CI: 0.569-0.577) for proposed T3a reclassification (p<0.001).

Conclusion: Reclassification of cT1→pT3a and cT2→ pT2 into a new T2 RCC while maintaining cT2→pT3a and cT3a→pT3a RCC in T3a RCC resulted in improved performance of the realigned model for OS. Revised TNM criteria for pT2 and T3a RCC should be considered.

病理上被抢风头的T3a肾细胞癌的重新分类与结果的增强一致性相关:国家癌症数据库的分析
目的:比较病理性T3a肾细胞癌(RCC)临床分期的预后,并提出基于生存结果的T3a肾细胞癌的重新分类,因为目前T3a肾细胞癌的预后可能因初始临床表现而异。方法:使用国家癌症数据库,根据AJCC临床T分期对pT2和pT3aN0M0型RCC患者进行分类。主要终点为总生存期(OS)。多变量分析(MVA)评估全因死亡率(ACM)的预测因子,控制临床T期。Kaplan-Meier分析(KMA)评估cT1-抢位pT3a (cT1→pT3a)、cT2-抢位pT3a (cT2→pT3a)、临床/病理T2 (cT2→pT2)和临床/病理T3a (cT3a→pT3a) RCC之间的差异,并基于临床分期组之间生存结果的聚类创建改良的T3a RCC。采用ROC/AUC分析比较AJCC第8版分期与建议分期的预测值。结果:共分析了45,097例pT3a疾病患者(9,730例cT1→pT3a;7,209 cT2→pT3a, 19,857 cT2→pT2;8301 cT3a→pT3a)。MVA对OS [cT1→pT3a(参照)]显示cT2→pT3a (HR=1.27, pth版TNM分期和AUC为0.573 (95% CI: 0.569-0.577)。结论:cT1→pT3a和cT2→pT2重新分类为新的T2 RCC,同时维持cT2→pT3a和cT3a→pT3a RCC在T3a RCC中可改善OS重组模型的性能。应考虑修订pT2和T3a RCC的TNM标准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.80
自引率
3.70%
发文量
297
审稿时长
7.6 weeks
期刊介绍: Urologic Oncology: Seminars and Original Investigations is the official journal of the Society of Urologic Oncology. The journal publishes practical, timely, and relevant clinical and basic science research articles which address any aspect of urologic oncology. Each issue comprises original research, news and topics, survey articles providing short commentaries on other important articles in the urologic oncology literature, and reviews including an in-depth Seminar examining a specific clinical dilemma. The journal periodically publishes supplement issues devoted to areas of current interest to the urologic oncology community. Articles published are of interest to researchers and the clinicians involved in the practice of urologic oncology including urologists, oncologists, and radiologists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信